Continue Current Diabetes Medications
Yes, this 60-year-old woman should absolutely continue both Jardiance 10 mg daily and metformin 500 mg twice daily. Her A1c reduction from 8.3% to 7.4% over 8 months represents meaningful progress toward glycemic control, but she has not yet achieved the recommended target of <7% for most adults with type 2 diabetes 1.
Rationale for Continuation
Current Glycemic Status
Her A1c of 7.4% places her above the general target of <7% recommended by the American Diabetes Association for most non-pregnant adults with type 2 diabetes 1. The evidence shows a curvilinear relationship between A1c and microvascular complications, with continued benefit from lowering A1c from 7.4% toward 7% 2. She requires treatment intensification, not de-escalation.
Metformin Should Be Maintained
- Metformin remains the cornerstone of type 2 diabetes management and should be continued when used in combination with other agents, including SGLT2 inhibitors, unless contraindicated or not tolerated 3, 4
- The 2025 ADA guidelines explicitly state metformin should be continued when combined with other medications 1
- Her current dose of 1000 mg daily (500 mg twice daily) is below the typical therapeutic range of 1500-2000 mg daily, suggesting room for dose optimization if tolerated 1
- Metformin provides cardiovascular mortality benefits, is weight neutral, and does not cause hypoglycemia 1
Jardiance (Empagliflozin) Provides Critical Benefits Beyond Glucose Control
The cardiovascular and renal protective effects of empagliflozin are independent of A1c reduction and represent a primary reason to continue this medication 5, 6:
- Cardiovascular benefits: The EMPA-REG OUTCOME trial demonstrated a 38% reduction in cardiovascular death and 32% reduction in all-cause mortality 5
- Heart failure benefits: 35% reduction in heart failure hospitalization 5
- Renal protection: Significant reduction in worsening nephropathy 5
- These benefits were observed in patients with baseline A1c ≥6.5%, with over 70% taking metformin at baseline 7
Treatment Intensification Is Indicated
When A1c remains ≥0.4% above target (as in this case: 7.4% vs. 7.0% goal), treatment intensification should not be delayed 1, 4. The 2025 ADA guidelines state that when A1c is ≥1.5% above goal, dual-combination therapy or more potent agents are typically required 1. While she's already on dual therapy, options include:
- Optimize metformin dose to 1500-2000 mg daily if tolerated (currently only at 1000 mg daily) 1
- Consider increasing Jardiance from 10 mg to 25 mg daily, which provides incrementally greater A1c reduction (0.59-0.84% vs. 0.48-0.73%) 8
- Add a third agent if optimization of current medications doesn't achieve target, preferably a GLP-1 receptor agonist given additional cardiovascular benefits 1, 7
Specific Monitoring Recommendations
- Recheck A1c in 3 months after any medication adjustment 1, 4
- Monitor vitamin B12 levels periodically given long-term metformin use, especially if she develops anemia or peripheral neuropathy 1, 7
- Assess kidney function (eGFR) to ensure both medications remain appropriate (metformin safe ≥30 mL/min/1.73 m²; empagliflozin can be continued at lower eGFR levels) 1, 9
- Monitor for hypoglycemia if adding additional agents, though risk remains low with this combination 1
Common Pitfalls to Avoid
Do not prematurely discontinue effective therapy based on partial improvement. The goal is A1c <7%, not simply "better than before." Studies consistently show that treatment intensification delays lead to prolonged exposure to hyperglycemia and increased microvascular complications 1, 2.
Do not consider de-intensification unless A1c falls below 6.5%, at which point the harms may outweigh benefits 10. At 7.4%, she remains in a range where further glucose lowering provides clinical benefit without excessive risk.
Recognize that SGLT2 inhibitors like Jardiance provide benefits independent of glucose lowering, particularly for cardiovascular and renal protection 5, 6, 7. Even if her A1c were at goal, continuing empagliflozin would be appropriate for these organ-protective effects, especially if she has cardiovascular disease, heart failure, or chronic kidney disease.